<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38370105</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1937-8688</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>Suppl 2</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>The Pan African medical journal</Title><ISOAbbreviation>Pan Afr Med J</ISOAbbreviation></Journal><ArticleTitle>Deployment of novel oral polio vaccine type 2 under emergency use listing in Nigeria: the rollout experience.</ArticleTitle><Pagination><StartPage>3</StartPage><MedlinePgn>3</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.11604/pamj.supp.2023.45.2.38033</ELocationID><Abstract><AbstractText>In 2011, a dedicated consortium of experts commenced work on the development of the novel oral poliovirus vaccine type 2 (nOPV2). After careful and rigorous analysis of data to enable early, targeted use of the vaccine, World Health Organization´s (WHO´s) Strategic Advisory Group of Experts on Immunization (SAGE) reviewed data from accelerated clinical development of nOPV2 and endorsed entering assessment under WHO´s Emergency Use Listing (EUL) procedure. In November 2020, nOPV2 received an interim recommendation for use under EUL to enable rapid field availability and potential wider rollout of the vaccine. In December 2020, Nigeria initiated preparation to meet all criteria for initial use of nOPV2 in the country and the documentation process to verify meeting them. The process entailed addressing the status of meeting 25 readiness criteria in nine categories for nOPV2 use in Nigeria for response efforts to ongoing cVDPV2 outbreaks. During January-February 2021, Nigeria submitted the required documentation for all required indicators for nOPV2 initial use. In February 2021, the country obtained approval from the GPEI nOPV2 Readiness Verification Team to introduce nOPV2 and in March 2021, rolled out the novel vaccine in mass vaccination campaigns for outbreak response in Bayelsa, Delta, Niger, Sokoto and Zamfara states, and one area council in the Federal Capital Territory (FCT). The lessons learned from this rollout experience in Nigeria are being applied as the country streamlines and strengthens the nOPV2 rollout process across the remaining states.</AbstractText><CopyrightInformation>©Adeyelu Asekun et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Asekun</LastName><ForeName>Adeyelu</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>US Centers for Disease Control and Prevention, Georgia, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nkwogu</LastName><ForeName>Loveday</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>World Health Organization, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bawa</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>World Health Organization, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Usman</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>CORE Group Polio Project, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edukugho</LastName><ForeName>Aboyowa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>African Field Epidemiology Network, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ocheh</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>World Health Organization, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banda</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>World Health Organization, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nganda</LastName><ForeName>Gatei Wa</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>US Centers for Disease Control and Prevention, Georgia, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nsubuga</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>National Primary Health Care Development Agency, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Archer</LastName><ForeName>Roodly</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>US Centers for Disease Control and Prevention, Georgia, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nebechukwu</LastName><ForeName>Tonia</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Rotary International, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohammed</LastName><ForeName>Aminu</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Global Public Health Solutions, Georgia, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shuaib</LastName><ForeName>Faisal</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Rotary International, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bolu</LastName><ForeName>Omotayo</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>US Centers for Disease Control and Prevention, Georgia, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adamu</LastName><ForeName>Usman</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Rotary International, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Uganda</Country><MedlineTA>Pan Afr Med J</MedlineTA><NlmUniqueID>101517926</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009549" MajorTopicYN="N" Type="Geographic">Nigeria</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Nigeria</Keyword><Keyword MajorTopicYN="N">Prevalence</Keyword><Keyword MajorTopicYN="N">antibodies</Keyword><Keyword MajorTopicYN="N">disease outbreaks</Keyword><Keyword MajorTopicYN="N">immunity</Keyword><Keyword MajorTopicYN="N">immunization</Keyword><Keyword MajorTopicYN="N">oral</Keyword><Keyword MajorTopicYN="N">polio virus vaccine</Keyword><Keyword MajorTopicYN="N">poliomyelitis</Keyword><Keyword MajorTopicYN="N">risk factors</Keyword><Keyword MajorTopicYN="N">serotype</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>20</Day><Hour>11</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>19</Day><Hour>4</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>7</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38370105</ArticleId><ArticleId IdType="pmc">PMC10874098</ArticleId><ArticleId IdType="doi">10.11604/pamj.supp.2023.45.2.38033</ArticleId><ArticleId IdType="pii">PAMJ-45-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rotary World Polio Day cheers major achievements toward global polio eradication. 2019. Accessed Sep 8, 2021.</Citation></Reference><Reference><Citation>World Health Organization Africa eradicates wild poliovirus. August 25 2020, Accessed Sep 8, 2021.</Citation></Reference><Reference><Citation>Alonge O. What can over 30 years of efforts to eradicate polio teach us about global health. BMC Public Health. 2020 Aug 12;20(Suppl 2):1177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7419726</ArticleId><ArticleId IdType="pubmed">32787897</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative Circulating vaccine-derived poliovirus. March 28 2021, Accessed Sep 8 2021.</Citation></Reference><Reference><Citation>World Health Organization Weekly GPEI Polio Analyses. Accessed Sep 8 2022.</Citation></Reference><Reference><Citation>Wassilak S, Pate MA, Wannemuehler K, Jenks J, Burns C, Chenoweth P, et al. Outbreak of Type 2 Vaccine-Derived Poliovirus in Nigeria: Emergence and Widespread Circulation in an Underimmunized Population. J Infect Dis. 2011 Apr 1;203(7):898–909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068031</ArticleId><ArticleId IdType="pubmed">21402542</ArticleId></ArticleIdList></Reference><Reference><Citation>Voorman A, Habib MA, Hussain I, Muhammad Safdar R, Ahmed JA, Weldon WC, et al. Immunity and field efficacy of type 2-containing polio vaccines after cessation of trivalent oral polio vaccine: A population-based serological study in Pakistan. Vaccine: X. 2020 Aug;5:100067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7240192</ArticleId><ArticleId IdType="pubmed">32462141</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleem AF, Yousafzai MT, Mach O, Khan A, Quadri F, Weldon WC, et al. Evaluation of vaccine derived poliovirus type 2 outbreak response options: A randomized controlled trial, Karachi, Pakistan. Vaccine. 2018 Mar;36(13):1766–71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5869272</ArticleId><ArticleId IdType="pubmed">29477307</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative nOPV2. 2020. Accessed Sep 8 2021.</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative GPEI strategy for control of cVDPV2 2020-2021. 2020. Accessed Sep 8, 2021.</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative nOPV2 Frequently Asked Questions (FAQ) October 2020 Accessed Sep 8 2021.</Citation></Reference><Reference><Citation>Konopka-Anstadt JL, Campagnoli R, Vincent A, Shaw J, Wei L, Wynn NT, et al. Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization. npj Vaccines. 2020 Dec;5(1):26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7083942</ArticleId><ArticleId IdType="pubmed">32218998</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Geneva: World Health Organization; 2020. Implementation of novel oral polio vaccine type 2 (nOPV2) for circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreak response: technical guidance for countries. Accessed Sep 8, 2021.</Citation></Reference><Reference><Citation>Yeh MT, Bujaki E, Dolan PT, Smith M, Wahid R, Konz J, et al. Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence. Cell Host Microbe. 2020;27(5):736–751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566161</ArticleId><ArticleId IdType="pubmed">32330425</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative Guide for Surveillance of Adverse Events of Special Interest (AESI) during novel Oral Polio Vaccine type 2 (nOPV2) Use. 2020. Accessed Sep 8, 2021.</Citation></Reference><Reference><Citation>World Health Organization . 2014. Principles and considerations for adding a vaccine to a national immunization programme: From decision to implementation and monitoring. Accessed Sep 8, 2021.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention . New Vaccine Surveillance Network: Overview. Jun 2017, Accessed Sep 8, 2021.</Citation></Reference><Reference><Citation>Jalloh M, Wilhelm E, Abad N, Prybylski D. Mobilize to vaccinate: lessons learned from social mobilization for immunization in low and middle-income countries. Hum Vaccin Immunother. 2020 May 3;16(5):1208–1214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7227704</ArticleId><ArticleId IdType="pubmed">31464551</ArticleId></ArticleIdList></Reference><Reference><Citation>Touray K, Mkanda O, Tegegn SG, Nsubga P, Erbeto TB, Banda R, et al. Tracking Vaccination Teams During Polio Campaigns in Northern Nigeria by Use of Geographic Information System Technology: 2013-2015. The Journal of Infectious Diseases. 2016 May 1;213(3):S67–s72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4818548</ArticleId><ArticleId IdType="pubmed">26609004</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, Wilkinson A, Bandyopadhyay AS, Konopka-Anstadt JL, Burns CC, et al. Updated characterization of outbreak response strategies for 2019-2029: Impacts of using a novel type 2 oral poliovirus vaccine strain. Risk Anal. 2021 Feb;41(2):329–348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7887065</ArticleId><ArticleId IdType="pubmed">33174263</ArticleId></ArticleIdList></Reference><Reference><Citation>Relief web Countries gear up to kick all forms of polio out of Africa, once and for all. March 2021, Accessed Sep 8, 2021.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>